Human immunodeficiency virus-1 core: The Trojan horse in virus–host interaction

Wei Wang¹, Yan Li¹, Zhe Zhang¹ and Wei Wei¹,²*

¹Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, Jilin, China, ²Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Institute of Translational Medicine, First Hospital, Jilin University, Changchun, Jilin, China

Human immunodeficiency virus-1 (HIV-1) is the major cause of acquired immunodeficiency syndrome (AIDs) worldwide. In HIV-1 infection, innate immunity is the first defensive line for immune recognition and viral clearance to ensure the normal biological function of the host cell and body health. Under the strong selected pressure generated by the human body over thousands of years, HIV has evolved strategies to counteract and deceive the innate immune system into completing its lifecycle. Recently, several studies have demonstrated that HIV capsid core which is thought to be a protector of the cone structure of genomic RNA, also plays an essential role in escaping innate immunity surveillance. This mini-review summarizes the function of capsid in viral immune evasion, and the comprehensive elucidation of capsid-host cell innate immunity interaction could promote our understanding of HIV-1’s pathogenic mechanism and provide insights for HIV-1 treatment in clinical therapy.

KEYWORDS
HIV, core, capsid, host factors, innate immunity

Introduction

Human immunodeficiency virus (HIV) is the major pathogen accounting for human immunodeficiency syndrome, and innate immunity is the first defensive line against pathogenic infection (Mogensen, 2009; Yin et al., 2020). The genic single-strand RNA (ssRNA), double-strands DNA (dsDNA) transcribed from ssRNA or viral components of HIV can act as pathogen-associated molecular patterns (PAMPs) that are recognized by pattern recognition receptors (PRRs) on the host cell. PAMPs stimulate an immediate immune response and activate the antiviral cascade to clear intra- and extra-cellular virions (Le Sage et al., 2014). During HIV-1 infection, PAMPs of each stage could be recognized by different specific receptors. In the entry and uncoating stage, genomic ssRNA could be detected by the RIG-I-like receptors (RLRs) family [retinoic acid-inducible gene 1 (RIG-1) and melanoma-differentiation-associated protein 5 (MDA5)] and Toll-like receptors (TLR) including TLR7 and TLR8 (Gringhuis et al., 2010; Muenchhoff et al., 2014; Altfeld and Gale, 2015; Meas et al., 2020). While the innate immune activation by HIV RNA is controversial, whether other uncharacterized RNA sensors are responsible for sensing HIV-1 intron-containing RNA remains to be determined (Akiyama et al., 2018; McCauley...
Recent studies demonstrated that HIV-1 recruits cellular 2′-O-methyltransferase FTSJ3, leading to 2′-O-methylation of viral RNA and thereby escaping MDA5-dependent innate immune sensing in host cells (Ringoard et al., 2019). After entry, HIV-1 transcriptional product could be recognized by interferon (IFN)-inducible protein 16 (IFI16), DEAD-box helicase (DDX) family, and cyclic GMP-AMP synthase (cGAS). Additionally, cGAS recognizes HIV-1 in the integration-and translation-stages (Brai et al., 2020; Siddiqui and Yamashita, 2021). After immune activation, the host cell induces antiviral signaling pathways to drive robust IFN, proinflammatory cytokines, and chemokines production for efficiently inhibiting HIV-1’s replication (Thompson et al., 2014; Hoang and Piaudini, 2019). In addition to modulation of antiviral signaling pathways, the restriction factors such as Serine Incorporator family (SERINC; Rosa et al., 2015; Usami et al., 2015), apolipoprotein B mRNA editing enzyme catalytic subunit 3 (APOBEC3s; Sheehy et al., 2002), tripartite motif-containing protein 5a (Trim5a; Sayah et al., 2004; Stremlau et al., 2004; Pertel et al., 2011), dGTP-dependent deoxynucleotide triphosphohydrolase SAM domain, HD domain-containing protein 1 (SAMHD1) and BST-2/tetherin limit viral reproduction and spread through their unique manners (Neil et al., 2008; Hultquist and Harris, 2009; Goldstone et al., 2011; Hrecka et al., 2011; Laguette et al., 2011; Su et al., 2014; Yin et al., 2020).

Under strong selection pressure, HIV has evolved strategies to evade immune surveillance for its successful replication. The HIV-1 accessory proteins involved in immune evasion have been thoroughly researched for many years. For example, Nef can exclude SERINC 3 and SERINC 5 from HIV virions (Jin et al., 2018), while Vif induces the degradation of APOBEC3s by usurping the host CRL5 E3 ligase (Yu et al., 2003). Meanwhile, Vpr targets host cell restriction factors, such as helicase-like transcription factor (HLTF), tet methylcytosine dioxygenase 2 (TET2) or nuclear factor-kappa B (NF-kB) signaling pathway to facilitate viral replication (Wang and Su, 2019; Yan et al., 2019; Khan et al., 2020). Furthermore, Vpx, the homologous protein of simian immunodeficiency virus (SIV) has the same ability to selectively inhibit cGAS activity by targeting functional domain of stimulator of IFN genes (STING) and triggers SAMHD1 degradation (Hrecka et al., 2011; Laguette et al., 2011; Hofmann et al., 2012; Wei et al., 2012; Su et al., 2019). Additionally, HIV Vpu could counteract the antiviral effects from BST-2 and also exhibits potent to inhibit IFN response by acting on NF-kB signaling pathway (Van Damme et al., 2008; Douglas et al., 2009; Iwabu et al., 2009; Langer et al., 2019). Thus, in HIV infection, the unstructured accessory proteins are broadly utilized to resist host innate immunity through multifaceted strategies. However, the anti-innate immunity of HIV-1’s structure protein—the capsid (CA) protein has been barely reported. In recent studies, CA has been identified as a restriction factor that participates in anti-innate immune response during HIV-1’s lifecycle. Here, we review the function of CA in HIV immune evasion, throughout understanding of interaction between HIV CA protein and host cell innate immune surveillance will make HIV’s pathogenic mechanism clearly, and also provide new sight for fighting AIDS disease in clinical therapy.

**Human immunodeficiency virus capsid**

During virus maturation, HIV structural polyprotein Gag synthesized in the cytoplasm is proteolyzed by protease (PR) into four domains-matrix (MA), CA, nucleocapsid (NC) and P6 with two short peptides-SP1 and SP2 (Ono et al., 2004), – 250 CA formed hexamers and 12 pentamers assembling into the fulleren-like, cone-shaped core structure to enclose viral ribonucleoprotein complex and associated proteins internally (Yang et al., 2012). CA composed of 231 residues folds into two domains at both ends of the peptide chain through a flexible linker (residues 146–150; Pornillos et al., 2009; Rossi et al., 2021), N-terminal domain of CA (NTDs) which contains seven α helices and a cyclophilin A (CypA)-binding loop forms hexamers through an NTD-NTD interface (Gamble et al., 1996), C-terminal domain of CA (CTDs) forms dimers with adjacent hexamers through a CTD–CTD interface (Gamble et al., 1997). The NTD–CTD interface formed by NTD and CTD from two subunits is a crucial mechanical element for generating lattice curvature, the inner structure formed by adjacent CA proteins provides a platform for binding host cell factors to evade immune sensors and complete the viral lifecycle (Bhattacharya et al., 2014). Hexamers formed by CA interaction are linked together by N-terminal residues of CA-CTD, and the lattice structure is stabilized through intra-CA monomers modulated by water molecules (Gres et al., 2015). Some amino acid residues in the CA of pentamers have been confirmed to interact with hexamers, and pentamers are localized at high curvature domains, suggesting that hexamers may form the high curvature for pentamers to insert or the pentamers themselves supply a high angle of curvature to maintain the stability of mature core. Moreover, maintaining the stability of the CA core is essential for viral biological functions, alteration of stability would dramatically reduce HIV-1 infectivity (Pornillos et al., 2011; Mattei et al., 2016; Dharan et al., 2017; Achuthan et al., 2019). In the past decade, CA core was thought to be merely a container for viral RNA, but recently, multiple roles of CA during infection have been identified. Importantly, CA-related immune evasion has attracted considerable attention in many research fields, and CA inhibitors have been thought to be a potential antiviral target. Therefore, the exact role of CA in protecting HIV-1 from the innate immune activity is discussed below.

**Capsid protects HIV from cGAS sensor**

In HIV infection, cGAS is the best-studied receptor in host innate immune responses (Gao et al., 2013; Herzner et al., 2015; Sumner et al., 2020). At first, cGAS protein is recruited to the CA in a polyglutamine-binding protein-1 (PQBP1) or Non-POU
(Pit-Oct-Unc) domain-containing octamer-binding protein (NONO)-dependent manner in the cytosol and nucleus respectively, enabling cGAS molecules to recognize the reverse transcriptional product of HIV (Yoh et al., 2015, 2022; Lahaye et al., 2018). Subsequently, cGAS binds to viral dsDNA and produces a second messenger 2′,3′cGAMP, 2′,3′cGAMP detected by ER-resident STING and triggers STING translocation to Golgi, activating TANK-binding kinase 1 (TBK1), leading to phosphorylation of IFN regulatory factor 3 (IRF3) which is subsequently translocated into the nucleus to activate the expression of IFN and IFN-stimulated genes to resist HIV infection (Siddiqui et al., 2019; Hopfner and Hornung, 2020). Additionally, the TLR and canonical Hippo signaling pathway enhance cGAS sensing of HIV to efficiently inhibit viral replication (Siddiqui and Yamashita, 2021).

During HIV infection, the viral CA core must maintain its stability to ensure an efficient infection. CA-derived core structure is required to protect the reverse transcription complex (RTC) and pre-integration complex (PIC) from degradation by host restriction factors (Francis and Melikyan, 2018). However, recent study has demonstrated a new function of HIV-1 CA, suggesting that CA protein plays an essential role in evading cGAS monitoring (Sumner et al., 2020). Disrupting CA formation through inhibition of HIV Gag cleavage by genetic manipulation (Gag mutant L363I and Myxoma resistance protein A) has been observed in PMA-treated THP-1 and U87 cells. Transcriptional upregulation of IFN-stimulated genes downstream of cGAS (C–X–C motif chemokine ligand 10, IFN-induced protein with tetratricopeptide repeats 2, and Myxoma resistance protein A) has been observed in PMA-treated THP-1 cells, thus leading to a strong IFN response after lopinavir treatment (Sumner et al., 2020). Similarly, small molecule inhibitor PF-74 causes IFN-stimulated gene activation in wildtype and MAVS−/− cells, but not in cGAS−/− cells, suggesting that malformation of CA structure induces an innate immune response via a cGAS-dependent pathway (Kumar et al., 2018; Siddiqui et al., 2019; Sumner et al., 2020). Importantly, HIV-1 infection does not trigger a cGAS-mediated immune response (Cingoz and Goff, 2019; Elsner et al., 2020). While HIV-2 fails to evade the immune recognition in macrophages and dendritic cells, mainly because of distinct features of the CAs of HIV-1 and HIV-2 (Lahaye et al., 2013). The innate immune sensor of the HIV CA, NONO, binds to the HIV-2 CA with more affinity than HIV-1 in the nucleus, enabling sensing of HIV DNA and subsequent activatation of cGAS-STING pathway (Lahaye et al., 2018). HIV-1's CA-dependent immune evasion strategy, where CA cloaks viral DNA from cGAS sensing successfully explains this phenomenon (Figure 1).

**Capsid-mediated viral dependent factors**

During HIV-1’s lifecycle, multiple virus-dependent factors of the host cell could be hijacked at different steps to promote viral replication through CA-dependent methods, some of which are manipulated to evade the immune response. Virus-dependent factors that participate in immune evasion are introduced below.

**Cleavage and polyadenyluation specificity factor subunit 6**

Cleavage and polyadenyluation specificity factor subunit 6 (CPSF6), a component of the cleavage factor 1 (CFIm), interacts with CA protein and is strictly conserved in lentiviruses (Lee et al., 2010; Saito et al., 2020). CPSF6 binds to HIV-1 CA through the CTD of CA (Iwabu et al., 2009), and assists HIV-1 infection during the uncoating steps (Saito and Yamashita, 2021). The interaction between CPSF6 and HIV-1 CA is essential for successful viral replication. Depleting CPSF6 induces strong IFN activity, suggesting CPSF6 provides an advantage to HIV-1 for avoiding immune activation. Compared to HIV-1 wildtype virus, depleting connection between HIV-1 and CPSF6 using HIV-1 CA mutants (N74D) is lethal for viral replication in primary human monocyte-derived macrophages (MDM). N74D mutant triggers IRF3 and RetA nuclear translocation, which activates the NF-κB signaling pathway and ultimately stimulates strong IFN production to suppress viral replication (Sumner et al., 2020). Moreover, depleting the CPSF6-CA interaction leads to HIV-1 RTC and PIC accumulating at the nuclear envelope in macrophages, while the IFN secretion induced by retention of many subviral complexes in the cytoplasm also results in poor infectivity (Bejarano et al., 2019).

**Cyclophilin A**

Cyclophilin A (CypA) belongs to the cellular cyclophilin family, essential for viral replication in a variety of viruses, such as hepatitis C virus (HCV), coronaviruses (CoVs) and HIV, and its polymorphisms affect viral susceptibility and disease progression (Le Sage et al., 2014; Mamatis et al., 2022). CypA interacts with CypA binding loops at the N-terminal of HIV-1 CA, as described above. The CypA-CA binding is crucial for HIV-1 replication in primary human macrophages and dendritic cells, HIV-1 mutant deficiency in CypA-CA binding stimulates type I IFN secretion and induces an antiviral state. In MDM infection, the HIV-1 mutant P90A impairs CA-CypA interaction, which stimulates IFN-β secretion and activates the immune response, resulting in efficient suppression of viral infection (Sumner et al., 2020). In a recent study, a CypA inhibitors, cyclosporine (CsA), and a non-immunosuppressive analog of CsA, Smbz-CsA could alter the CypA-CA affinity and elicit extreme antiviral activity in MDM, they also induce robust IFN-β production and completely inhibit HIV-1 infection (Li et al., 2009; Sumner et al., 2020). From the above, it can be observed HIV-1 CA-CypA interaction is essential for viral replication through protecting itself from innate immune recognition, however, the excellent anti-HIV-1 activity of CypA inhibitors in vitro is a promising prospect for clinical medicine
development (Carnes et al., 2018). Moreover, CypA could counteract Trim5α during HIV-1 infection, the exact function of CypA facilitating HIV-1 to evade the Trim5α restriction is discussed later (Li et al., 2016).

**Nuclear pore components**

The nuclear pore component or nucleoporin (NUP), a component of the nuclear pore complex, could be manipulated by HIV-1 during its nuclear import stage. Among the NUP family, HIV-1 CA directly interacts with NUP153 and NUP358, whereas the other NUPs are thought to serve as co-factors by genome-wide RNA interference screens (Kane et al., 2018). Depletion of CA interaction with NUP153 and NUP358 by HIV-1 mutants N74D or P90A leads to strong IFN production, reducing viral replication in MDM because NUP-CA interaction could efficiently block nuclear translocation of IRF3 and NF-κB (Gres et al., 2015). However, some studies have proposed that NUP-CA interaction is not the determining factor for immunosuppression, and the immune activation caused by HIV-1 mutants is ascribed to a defect of recruitment of CPSF6 through NUP358. Whether NUPs directly modulate immune responses remains controversial, thus; the exact mechanism of NUPs in immune evasion requires further study (Rasaiyaah et al., 2013; Shen et al., 2021).

Myxovirus resistance protein B (MXB/MX2), a dynamin-like GTPase, inhibits infection of HIV and primate lentivirus by blocking their trafficking and nuclear entry steps (Goujon et al., 2013; Kane et al., 2013; Liu et al., 2013; Wei et al., 2016; Yamashita and Engelman, 2017; Betancor et al., 2019, 2021). After the invasion, NUP153 and NUP358 are manipulated by HIV-1 to resist the IFN-induced MXB reaction to complete its lifecycle (Liu et al., 2013; Fribourgh et al., 2014). Except for NUP153 and NUP158, other NUP factors such as NUP62, NUP93, NUP153, NUP214, and NUP358 have been identified as HIV-1 co-factors in recent studies, which block MXB recognition and assist HIV-1 in completing its nuclear transportation through different NUP-dependent pathway (Engelman, 2021).
that, if necessary, multiple NUP factors could be employed by HIV-1 to evade MXB surveillance (Kane et al., 2018). Accordingly, it is easy to elucidate why HIV-1 epidemic clades in different regions exhibit variant characteristics of MXB-resistant activity (Kane et al., 2018; Rossi et al., 2021).

**Trim5α**

Trim5α is a non-human primate restriction factor that disrupts reverse transcription and blocks viral infection during early infection (Sayah et al., 2004; Berthoux et al., 2005; Novikova et al., 2019). HIV-1 CA is captured by the SPRY domain of polymerized Trim5α and causes premature uncoating, where the replicated elements inside the cone-shaped core are exposed to host cell's cytoplasm and the reverse transcription terminated. Although Trim5α exhibits a strong antiviral activity immediately after viral infection, it is a pity that, the interaction between CA and its co-factors results in the inability of human Trim5α (huTrim5α) to bind to HIV-1 CA directly; thus, its suppression of HIV-1 replication is weak (Kim et al., 2019). Compared to that of the wild-type virus, the HIV-1 mutant N74D bearing deficiencies in CPSF6 and CypA-interaction exhibits infectivity defect, whereas knockout of huTrim5α rescues infectivity of N74D in human CD4⁺ T cells, but depletion of CPSF6 does not affect HIV-1 reverse transcription, meaning that CPSF6 is not a key modulator against huTrim5α restriction. Otherwise, the small molecule inhibitor CsA and GS-Cyp A13 targeting CypA-CA interaction decrease HIV-1 infectivity in macrophages and CD4⁺ T cells, respectively (Kim et al., 2019), suggesting that CypA is an anti-HIV-1 target for huTrim5α (Ganser-Pornillos and Pornillos, 2019; Selyutina et al., 2022b). Moreover, in HIV-1 P90A mutant infection, Trim5α acts as PRR to induce IFN-β production through NF-kB and AP1 signaling pathway in a non-canonical autophagy-dependent method (Saha et al., 2020), which means intact CA-CypA is pivotal for resisting multiple innate antiviral pathways induced by huTrim5α in HIV-1 infection. Although the CypA-CA interaction protects HIV-1 from the restriction of Trim5α, CsA which has been previously used in clinical trials targeting CypA-CA, exhibits efficient anti-HIV-1 activity by triggering pre-mature uncoating and innate immune responses (McArthur et al., 2019; Link et al., 2020). This evidence demonstrates that Trim5α and CypA-CA interaction is a promising anti-HIV target for further anti-HIV-1 medical development.

**Disrupting stress granule**

After viral infection, the virus-induced production of reactive oxygen species and HIV-1 protease activity increase the intracellular stress, which leads to the assembly of translationally silent ribonucleoprotein and proteins into stress granule (SG; Le Sage et al., 2014; Rao et al., 2018). Stress granule formation suppresses viral replication, and therefore, HIV-1 manipulates multiple factors to disrupt SG production. The N-terminal CA of Gag disrupts canonical type I SGs through interaction with the host eukaryotic elongation factor 2 (eEF2; Valiente-Echeverria et al., 2014), and non-canonical type II SGs are blocked by Gag through disrupting hypophosphorylated 4EBP1 by targeting eIF4E (Cinti et al., 2016). Moreover, the interaction between CypA with the N-terminal of Gag is essential for the immune sensing in monocyte-derived dendritic cells. Importantly, CypA-CA binding mutant HIV-1 G89A and CA inhibitor CsA cause HIV-1 losing the ability of modulating SG production (Manel et al., 2010; Le Sage et al., 2014; Cinti et al., 2016).

**Discussion**

As an extracellular intruder, HIV-1 needs to minimize the cellular processes that induce innate immune responses to complete its lifecycle. From the membrane to the nucleus, the virus must undergo a long-range movement to arrive at its destination and cloak itself perfectly to avoid PRR recognition (Sabo et al., 2013). Under the selected pressure, HIV-1 has evolved unique strategies to counteract the innate immune system to complete its successful infection. The genetic material, accessory proteins, and replication-associated elements (PAMPs) are packed inside the CA core to deceive cGAS recognition. Additionally, the accessory protein, including Vpr, Vpu, Vif, Vpx, and Nef are packaged into the CA-derived core before its budding, to assist HIV in evading immune surveillance, which makes the proper core stability import for HIV-1 infection by keeping these accessory protein safely inside, and the host cell-dependent factors strictly binds to CA to counteract Trim5α for maintaining the stability of the viral structure (Rose et al., 2021). HIV-1 depends on CA-derived core to avoid the immune sensors encountered in host cytoplasm during its early infection, which is consistent with a recent study that CA core maintains its intact structure and escorts HIV-1 into the nucleus for its efficient infection, and increasing evidence demonstrated that an intact or nearly intact CA core passes through nuclear pore complexes to enter the nucleus, suggesting that HIV-1 CA provides unique strategies for protecting HIV-1 from innate immune recognition (Christensen et al., 2020; Shen et al., 2021).

Because of CA's important role in immune evasion, antiviral research targeting CA protein attracts increasing attentions from scientists and pharmaceutical institutions. Many small-molecule inhibitors have been developed and exhibit efficient antiviral activity in vitro and clinical trials. GS-CA and GS-62072, developed from PF74, disrupt the CA interaction with CPSF6 and NUP153, enhancing innate immune responses and ultimately eliminating the HIV-1; additionally, the long-acting activity makes them suitable for clinical treatment (Carnes et al., 2018). However, some epidemic variants breakthrough PF74 inhibition independent of reduction of PF74 binding, two SIVs that are not sensitive to PF74 and GS-CA have been recently identified (Siddiqui et al., 2019; Twizerimana et al., 2020). The newly emerged immune evasion strategies of HIV-1 transmitted variant
makes it difficult to develop broad-spectrum anti-HIV-1 medicine, but additional studies targeting diverse HIV-1 variants may uncover distinct mechanisms to escape restriction by these CA inhibitors (Twizerimana et al., 2020; Saito and Yamashita, 2021). Although conformational changes induced by CA mutant decrease the sensitivity to CA inhibitor (Selyutina et al., 2022a), and anti-HIV activity of CA inhibitor strictly dependent on cell types (Twizerimana et al., 2020), it is promising that further study of CA-related immune evasion will clearly elucidate HIV-1’s pathogenic mechanism and provide a theoretical basis for antiviral therapeutics.

Author contributions

We conceptualized the ideas. WeA performed the literature search and drafted the original manuscript, and drew the figure. WeA, YL, and ZZ revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Natural Science Foundation of China (81772183 and 31800150), the National Major Project for Infectious Disease Control and Prevention (2018ZX10731-101-001-016), the Department of Science and Technology of Jilin Province (nos. 20190304033YY and 20180101127JC), the Open Project of Key Laboratory of Organ Regeneration and Transplantation, Ministry of Education, the Program for JLU Science and Technology Innovative Research Team (2017TD-08), and Fundamental Research Funds for the Central Universities.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Achuthan, V., Perreira, J. M., Ahn, J. J., Brass, A. L., and Engelman, A. N. (2019). Capsid-Cpsf6 interaction: master regulator of nuclear Hiv-1 positioning and integration. J. Life Sci (Westlake Village) 1, 39–45. doi: 10.36606/jols/20190604

Akiyama, H., Müller, C. M., Ettinger, C. R., Belkina, A. C., Snyder-Cappione, J. E., and Gummeluru, S. (2018). Hiv-1 intron-containing RNA expression induces innate immunity activation and T cell dysfunction. Nat. Commun. 9, 3450. doi: 10.1038/s41467-018-05899-7

Altfeld, M., and Gale, M. (2015). Innate immunity against Hiv-1 infection. Nat. Immunol. 16, 554–562. doi: 10.1038/ni.3157

Bejarano, D. A., Peng, K., Laketa, V., Borner, K., Jost, K. L., Lucic, B., et al. (2019). Hiv-1 nuclear import in macrophages is regulated by Cpsf6-capsid interactions at the nuclear pore complex. eLife 8. doi: 10.7554/eLife.41800

Bertheux, L., Sebastian, S., Sokolskiška, E., and Luban, J. (2005). Cyclophilin a is required for Trim35α-mediated resistance to Hiv-1 in Old World monkey cells. Proc. Natl. Acad. Sci. U. S. A. 102, 14849–14853. doi: 10.1073/pnas.0505659102

Betancor, G., Dicks, M. D. J., Jimenez-Guareno, J. M., Ali, N. H., Apolonio, L., and Malim, M. H. (2019). The Gtpase domain of Mx2 interacts with the Hiv-1 capsid, enabling its short isoform to moderate antiviral restriction. Cell Rep. 29, 1923–1933.e3. doi: 10.1016/j.celrep.2019.10.099

Betancor, G., Jimenez-Guareno, J. M., Lynham, S., Antrubus, R., Khan, H., Sobala, A., et al. (2021). Mx2-mediated innate immunity against Hiv-1 is regulated by serine phosphorylation. Nat. Microbiol. 6, 1031–1042. doi: 10.1038/s41564-021-00957-5

Bhattacharya, A., Alam, S. L., Frick, T., Zadrozný, K., Sedricki, J., Taylor, A. B., et al. (2014). Structural basis of Hiv-1 capsid recognition by Pf74 and Cpsf6. Proc. Natl. Acad. Sci. U. S. A. 111, 18625–18630. doi: 10.1073/pnas.1419945112

Braii, A., Riva, V., Saladini, F., Zamperini, C., Trivisani, C. I., Garbelli, A., et al. (2020). Ddx20 inhibitors, an effective way to overcome Hiv-1 resistance targeting host proteins. Eur. J. Med. Chem. 200, 112319. doi: 10.1016/j.ejmech.2020.112319

Carnes, S. K., Shebeh, J. H., and Aiken, C. (2018). Inhibitors of the Hiv-1 capsid, a target of opportunity. Curr. Opin. HIV AIDS 13, 359–365. doi: 10.1097/COH.0000000000000472

Christensen, D. E., Ganse-Pornillos, B. K., Johnson, J. S., Pornillos, O., and Soudquist, W. I. (2020). Reconstitution and visualization of Hiv-1 capsid-dependent replication and integration in vitro. Science 370, 6513. doi: 10.1126/science.abq8420

Cingoz, O., and Goff, S. P. (2019). Hiv-1 is a poor inducer of innate immune responses. mBio 10. doi: 10.1128/mBio.00284-18

Cinti, A., Le Sage, V., Ghaem, M., and Mouland, A. J. (2016). Hiv-1 gag blocks selenite-induced stress granule assembly by altering the Mrna cap-binding complex. mBio 7, e00329. doi: 10.1128/mBio.00329-16

Dharan, A., Opp, S., Abdel-Rahim, O., Keceli, S. K., Immam, S., Diaz-Griffiero, F., et al. (2017). Bicaudal D2 facilitates the cytoplasmic trafficking and nuclear import of Hiv-1 genomes During infection. Proc. Natl. Acad. Sci. U. S. A. 114, E10707–E10716. doi: 10.1073/pnas.1712033114

Douglas, J. L., Viswanathan, K., McCarroll, M. N., Gustin, J. K., Fruh, K., and Moses, A. V. (2009). Vpu directs the degradation of the human immunodeficiency virus restriction factor Bst-2/Tetherin via a BetaTrcp-dependent mechanism. J. Virol. 83, 7931–7947. doi: 10.1128/JVI.00422-09

Ehser, C., Ponurrangam, A., Kazmierski, J., Zillinger, T., Jansen, J., Todt, D., et al. (2020). Absence of Cgsa-mediated type 1 innate responses in Hiv-1-infected T cells. Proc. Natl. Acad. Sci. U. S. A. 117, 19475–19486. doi: 10.1073/pnas.2002481117

Engelman, A. N. (2021). Hiv capsid and integration targeting. Viruses 13:125. doi: 10.3390/v13010125

Francis, A. C., and Melikyan, G. B. (2018). Single Hiv-1 imaging reveals progression of infection through Ca-dependent steps of docking at the nuclear pore, Uncoating, and nuclear transport. Cell Host Microbe 23, 536–548.e6. doi: 10.1016/j.chom.2018.03.009

Frigouhour, J. L., Nguyen, H. C., Matreyek, K. A., Alvarez, F. J. D., Summers, B. J., Dewdney, T. G., et al. (2014). Structural insight into Hiv-1 restriction by Mxb. Cell Host Microbe 16, 627–638. doi: 10.1016/j.chom.2014.09.021

Gamble, T. R., Vajdos, F. F., Yoo, S., Worthylake, D. K., Housewart, M., Sundquist, W. I., et al. (1996). Crystal structure of human Cyclophilin a bound to the amino-terminal domain of Hiv-1 capsid. Cell 87, 1285–1294. doi: 10.1016/a0092-8674(96)08182-1

Gamble, T. R., Yoo, S., Vajdos, F. F., von Schwebler, U. K., Worhylake, D. K., Wang, H., et al. (1997). Structure of the carboxyl-terminal dimerization domain of the Hiv-1 capsid protein. Science 278, 849–853. doi: 10.1126/science.278.5339.849
The capsids of Hiv-1 and Hiv-2 determine immune detection of the viral CdnA by Segeral, E., et al. (2011). Samhd1 is the dendritic- and myeloid-cell-specific Hiv-1 incomplete reverse transcription products. Nat. Microbiol. 10.7554/eLife.60821

Tulleken, C., et al. (2020). Hiv-1 Vpr antagonizes innate immune activation by infection and the antiviral activity of Mx2. Kvaratskhelia, M., et al. (2018). Nuclear pore heterogeneity influences Hiv-1 functions of Cgas-Sting Signalling. Hofmann, H., Logue, E. C., Bloch, N., Daddacha, W., Polsky, S. B., Schultz, M. L., et al. (2012). The Vpx Lentiviral accessory protein targets Samhd1 for degradation during the virus replication cycle. Matthews, S., Glass, A., Hagen, W. K., Krausslich, H. G., and Briggs, J. A. (2016). The Vpx Lentiviral accessory protein targets Samhd1 for degradation in the nucleus. J. Virol. 86, 12552–12560. doi: 10.1128/JVI.01615-17

Hofnper, K. P., and Horruung, V. (2020). Molecular mechanisms and cellular functions of Cgast-Sting Signalling. Nat. Rev. Mol. Cell Biol. 21, 501–521. doi: 10.1038/s41564-019-0592-5

Diehl, W. E., et al. (2018). Intron-containing Rna from the Hiv-1 provirus activates beyond Pf74. Ashkenazi, A., and Bieniasz, P. D. (2008). Tetherin inhibits retrovirus infection by targeting human T cells and reverse latency. Nat. Commun. 11:147. doi: 10.1038/ncomms13857

Mogensen, T. H. (2009). Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22, 240–273. doi: 10.1128/CMR.00046-08

Mucnochhoff, M., Prendergast, A. J., and Gouldier, P. J. (2014). Immunity to Hiv in early life. Front. Immunol. 5:581. doi: 10.3389/fimmu.2014.00591

Neil, S. J., Zang, T., and Bieniarz, P. D. (2008). Tetherin inhibits retrovirus release and is antagonized by Hiv-1 Vpu. Nature 451, 425–430. doi: 10.1038/ nature06553

Novikova, M., Zhang, Y., Freed, E. O., and Peng, K. (2019). Multiple roles of Hiv-1 capsid During the virus replication cycle. Virol. Sin. 34, 119–134. doi: 10.1007/s12639-014-00839-1

Kim, K., Dauphin, A., Comar, S. M., Yurkovetsky, L., Deld, W. E., et al. (2018). Intron-containing Rna from the Hiv-1 provirus activates Tetherin in antiviral innate immune cells. Nat. Rev. Mol. Cell Biol. 19, 121–128. doi: 10.1038/nrc.2017.105

Liang, Z., Pan, Q., Ding, S., Qian, J., Xu, F., Zhou, J., et al. (2020). Clinical targeting of Hiv capsid protein with a long-acting small molecule. Nature 584, 614–618. doi: 10.1038/s41586-020-2443-1

Zhao, W., Lan, Y., Li, Q., Wu, Z., Zhang, Z., and Peng, D. (2019). Hiv-1 capsid protein reveals conformational variability. Science 349, 99–103. doi: 10.1126/science.aah4972

Liu, Y., Li, A., and Sodroski, J. (2009). Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by Cyclophilin A. J. Virol. 83, 10951–10962. doi: 10.1128/JVI.00682-09

Link, J. O., Rhee, M. S., Tse, W. C., Zheng, J., Somozas, J. R., Rowe, W., et al. (2020). Clinical targeting of Hiv capsid protein with a long-acting small molecule. Nature 584, 614–618. doi: 10.1038/s41556-020-2044-x

Wang et al. 10.3389/fmicb.2022.1002476

Yadav, S. S., Bitzegeio, J., Kutluay, S. B., Zang, T., and Wilson, S. J., et al. (2018). Hiv-1 Nc-induced stress granule assembly and translation arrest are inhibited by the Samhd1 protein. Nature 520, 559–562. doi: 10.1038/nature12542

Gres, A., T. E. K., E. S., K. A., Kublwa, M., J. D., Mitu, S., and Benet, T. S., et al. (2013). Human Mx2 is an interferon-induced post-entry inhibitor of Hiv-1 infection. Nature 520, 559–562. doi: 10.1038/nature12542

Diehl, W. E., et al. (2018). Intron-containing Rna from the Hiv-1 provirus activates beyond Pf74. Bloch, N., et al. (2012). The Vpx Lentiviral accessory protein targets Samhd1 for degradation during the virus replication cycle. J. Virol. 86, 12552–12560. doi: 10.1128/JVI.01615-17

Hofnper, K. P., and Horruung, V. (2020). Molecular mechanisms and cellular functions of Cgast-Sting Signalling. Nat. Rev. Mol. Cell Biol. 21, 501–521. doi: 10.1038/s41564-019-0592-5
Su, J., Rui, Y., Lou, M., Yin, L., Xiong, H., Zhou, Z., et al. (2019). Hiv-2/Siv Virs targets a novel functional domain of Stem to selectively inhibit Cgag-Sting-mediated NF-Kappab signalling. Nat. Microbiol. 4, 2552–2564. doi:10.1038/s41564-019-0585-4

Sunnier, R. P., Harrison, L., Touzéy, E., Peacock, T. P., Spencer, M., Zuliani-Alvarez, L., et al. (2020). Disrupting Hiv-1 capsid formation causes Cgas-sensing of viral DNA. EMBO J. 39, e103958. doi: 10.1525/embj.2019103958

Thompson, M. R., Sharma, S., Atanand, M., Jensen, S. B., Carpenter, S., Knepe, D. M., et al. (2014). Interferon gamma-inducible protein (B6) 16 transcriptionally regulates type I Interferons and other interferon-stimulated genes and controls the interferon response to both DNA and RNA viruses. J. Biol. Chem. 289, 23568–23581. doi:10.1074/jbc.M114.554147

Tzvirimiana, A. P, Scheck, R., Becker, D., Zhang, Z., Wammers, M., Avetar, L., et al. (2020). Cell type-dependent escape of capsid inhibitors by simian immunodeficiency virus. Sci. Adv. 6, eaba9118. doi:10.1126/sciadv.aba9118

Usami, Y., Wu, Y. and Gottinger, H. G. (2015). Sertinc3 and Sertinc5 restrict Hiv-1 infection and are counteracted by Nef. Nature 526, 218–223. doi:10.1038/nature15400

Valiente-Echeverria, F., Melnychuk, L., Vyboh, K., Ajamian, L., Gallouzi, I. E., Bernard, N., et al. (2014). Eef2 and Ras-gap Sh3 domain-binding protein (G3bp1) modulate stress granule assembly During Hiv-1 infection. Nat. Commun. 5, 4819. Epub 2014/09/18. doi:10.1038/ncomms8189

Van Damme, N., Goff, D., Katsura, C., Jorgensen, R. L., Mitchell, R., Johnson, M. C., et al. (2008). The interferon-induced protein Bst-2 restricts Hiv-1 release and is Downregulated from the cell surface by the viral Vpu protein. Cell Host Microb. 3, 245–252. doi:10.1016/j.chom.2008.03.001

Wang, Q., and Su, L. (2019). Vpr enhances Hiv-1 Env processing and Virion infectivity in macrophages by modulating Tert-dependent ltfm3 expression. mBio 10:4. doi:10.1128/mBio.01344-19

Wei, W., Guo, H., Han, X., Liu, X., Zhou, X., Zhang, W., et al. (2012). A novel Dcaf1-binding motif required for Vpx-mediated degradation of nuclear Samhd1 and Vpr-induced G2 arrest. Cell Microbiol. 14, 1745–1756. doi:10.1111/j.1462-5822.2012.01835.x

Wei, W., Guo, H., Ma, M., Markham, R., and Yu, X. F. (2016). Accumulation of Mbx/Mmx2-resistant Hiv-1 capsid variants During expansion of the Hiv-1 epidemic in human populations. ELife 5, 230–236. doi:10.7554/eLife.2004.02070

Yamashita, M., and Engelman, A. N. (2017). Capsid-resistant host factors in Hiv-1 infection. Trends Microbiol. 25, 741–755. doi:10.1016/j.tim.2017.04.004

Yan, J., Shun, M. C., Zhang, Y., Hao, C., and Skowronska, J. (2019). Hiv-1 Vpr counteracts Hlf-mediated restriction of Hiv-1 infection in T cells. Proc. Natl. Acad. Sci. U. S. A. 116, 9568–9577. doi:10.1073/pnas.1804011116

Yang, R., Shi, J., Byeon, I. J., Ahn, J., Sheehan, J. H., Meleir, J. et al. (2012). Second-site suppressors of Hiv-1 capsid mutations: restoration of intracellular activities without correction of intrinsic capsid stability defects. Retrovirology 9, doi:10.1186/1742-4690-9-30

Yin, X., Langer, S., Zhang, Z., Herbert, K. M., Yoh, S., Konig, R., et al. (2020). Sensor sensibility-Hiv-1 and the innate immune response. Cell 179, 2348–2355. doi:10.1016/j.cell.2019.12.050

You, S. M., Mamede, J. I., Lau, D., Ahn, N., Sanchez-Aparicio, M. T., Temple, J., et al. (2022). Recognition of Hiv-1 capsid by Pap7p1 licenses an innate immune sensing of nascent Hiv-1 DNA. Mol. Cell. 82, 2871–2884.e6. doi:10.1016/j.molcel.2022.06.010

You, S. M., Schneider, M., Seifried, J., Soonthornvacharin, S., Aekele, R. E., Ohlveris, K. C., et al. (2015). Pap7p1 is a proximal sensor of the Cgag-dependent innate immune response to Hiv-1. Cell 161, 1293–1305. doi:10.1016/j.cell.2015.04.030

Yu, X., Yu, Y., Liu, B., Kun, K., Wong, W., Mao, P., et al. (2003). Induction of Apobec3g ubiquitination and degradation by an Hiv-1 Vif-Cu5-Scf complex. Science 302, 1056–1060. doi:10.1126/science.1089591